A citation-based method for searching scientific literature


List of co-cited articles
46 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
Francesco Cosentino, Peter J Grant, Victor Aboyans, Clifford J Bailey, Antonio Ceriello, Victoria Delgado, Massimo Federici, Gerasimos Filippatos, Diederick E Grobbee, Tina Birgitte Hansen,[...]. Eur Heart J 2020
75


Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
50

Clinical Implications of an Acute Dip in eGFR after SGLT2 Inhibitor Initiation.
Hiddo J L Heerspink, David Z I Cherney. Clin J Am Soc Nephrol 2021
19
50

Preventing and treating kidney disease in patients with type 2 diabetes.
Pierre Delanaye, André J Scheen. Expert Opin Pharmacother 2019
20
50

Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE-HF trial.
Michael E Nassif, Sheryl L Windsor, Fengming Tang, Mansoor Husain, Silvio E Inzucchi, Darren K McGuire, Bertram Pitt, Benjamin M Scirica, Bethany Austin, Michael W Fong,[...]. Diabetes Obes Metab 2021
8
50

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl,[...]. Circulation 2014
792
50

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
Brendon L Neuen, Tamara Young, Hiddo J L Heerspink, Bruce Neal, Vlado Perkovic, Laurent Billot, Kenneth W Mahaffey, David M Charytan, David C Wheeler, Clare Arnott,[...]. Lancet Diabetes Endocrinol 2019
321
50

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
Theresa A McDonagh, Marco Metra, Marianna Adamo, Roy S Gardner, Andreas Baumbach, Michael Böhm, Haran Burri, Javed Butler, Jelena Čelutkienė, Ovidiu Chioncel,[...]. Eur Heart J 2021
955
50

Relative Hypoxia and Early Diabetic Kidney Disease in Type 1 Diabetes.
Carissa Vinovskis, Lu-Ping Li, Pottumarthi Prasad, Kalie Tommerdahl, Laura Pyle, Robert G Nelson, Meda E Pavkov, Daniel van Raalte, Marian Rewers, Marlon Pragnell,[...]. Diabetes 2020
15
50

Sodium-glucose co-transporter-2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis.
Dario Giugliano, Miriam Longo, Paola Caruso, Maria Ida Maiorino, Giuseppe Bellastella, Katherine Esposito. Diabetes Obes Metab 2021
11
50


Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus.
Charuhas V Thakar, Annette Christianson, Jonathan Himmelfarb, Anthony C Leonard. Clin J Am Soc Nephrol 2011
300
50

Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis.
Avivit Cahn, Cheli Melzer-Cohen, Rena Pollack, Gabriel Chodick, Varda Shalev. Diabetes Obes Metab 2019
45
50


Kidney outcomes using a sustained ≥40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trials.
David Z I Cherney, Samuel Dagogo-Jack, Darren K McGuire, Francesco Cosentino, Richard Pratley, Weichung J Shih, Robert Frederich, Mario Maldonado, Jie Liu, Shuai Wang,[...]. Clin Cardiol 2021
10
50

The hyperfiltration theory: a paradigm shift in nephrology.
B M Brenner, E V Lawler, H S Mackenzie. Kidney Int 1996
570
50

Predicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron.
Anita T Layton, Volker Vallon, Aurélie Edwards. Am J Physiol Renal Physiol 2016
78
50

Cardiorenal Syndrome Revisited.
Faiez Zannad, Patrick Rossignol. Circulation 2018
117
50

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
50


Biomarkers and physiopathology in the cardiorenal syndrome.
Antoine Bouquegneau, Jean-Marie Krzesinski, Pierre Delanaye, Etienne Cavalier. Clin Chim Acta 2015
20
50

Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database.
A Perlman, S N Heyman, I Matok, J Stokar, M Muszkat, A Szalat. Nutr Metab Cardiovasc Dis 2017
51
50

Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
947
50

The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors?
Anne C Hesp, Jennifer A Schaub, Pottumarthi V Prasad, Volker Vallon, Gozewijn D Laverman, Petter Bjornstad, Daniël H van Raalte. Kidney Int 2020
46
50

Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
Stefan D Anker, Javed Butler, Gerasimos Filippatos, João P Ferreira, Edimar Bocchi, Michael Böhm, Hans-Peter Brunner-La Rocca, Dong-Ju Choi, Vijay Chopra, Eduardo Chuquiure-Valenzuela,[...]. N Engl J Med 2021
449
50

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
50

An update on the safety of SGLT2 inhibitors.
André J Scheen. Expert Opin Drug Saf 2019
66
50

Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis.
Girish N Nadkarni, Rocco Ferrandino, Alexander Chang, Aditya Surapaneni, Kinsuk Chauhan, Priti Poojary, Aparna Saha, Bart Ferket, Morgan E Grams, Steven G Coca. Diabetes Care 2017
91
50

Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics.
Gert J Mayer, Christoph Wanner, Matthew R Weir, Silvio E Inzucchi, Audrey Koitka-Weber, Stefan Hantel, Maximilian von Eynatten, Bernard Zinman, David Z I Cherney. Kidney Int 2019
58
50

We Can Finally Stop Worrying About SGLT2 Inhibitors and Acute Kidney Injury.
Vikas S Sridhar, Katherine R Tuttle, David Z I Cherney. Am J Kidney Dis 2020
15
50

Use of sodium-glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study.
Carina Iskander, David Z Cherney, Kristin K Clemens, Stephanie N Dixon, Ziv Harel, Nivethika Jeyakumar, Eric McArthur, Flory Tsobo Muanda, Chirag R Parikh, J Michael Paterson,[...]. CMAJ 2020
26
50

Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment.
Lennart Tonneijck, Marcel H A Muskiet, Mark M Smits, Erik J van Bommel, Hiddo J L Heerspink, Daniël H van Raalte, Jaap A Joles. J Am Soc Nephrol 2017
292
50

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
50

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
Christopher P Cannon, Richard Pratley, Samuel Dagogo-Jack, James Mancuso, Susan Huyck, Urszula Masiukiewicz, Bernard Charbonnel, Robert Frederich, Silvina Gallo, Francesco Cosentino,[...]. N Engl J Med 2020
440
50

Sodium-glucose cotransporter 2 inhibitors: renal outcomes according to baseline albuminuria.
Pierre Delanaye, Karl Martin Wissing, Andre J Scheen. Clin Kidney J 2021
5
50


Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
Deepak L Bhatt, Michael Szarek, Bertram Pitt, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Silvio E Inzucchi, Mikhail N Kosiborod,[...]. N Engl J Med 2021
253
50

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
50

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
50

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
50

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
50

The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.
Erik J M van Bommel, Marcel H A Muskiet, Michaël J B van Baar, Lennart Tonneijck, Mark M Smits, Anna L Emanuel, Andrea Bozovic, A H Jan Danser, Frank Geurts, Ewout J Hoorn,[...]. Kidney Int 2020
127
50

Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: A randomised, double-blind, placebo-controlled crossover trial.
Jens Christian Laursen, Niels Søndergaard-Heinrich, Joana Mendes Lopes de Melo, Bryan Haddock, Ida Kirstine Bull Rasmussen, Farzaneh Safavimanesh, Christian Stevns Hansen, Joachim Størling, Henrik Bo Wiberg Larsson, Per-Henrik Groop,[...]. EClinicalMedicine 2021
10
50

Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.
Hiddo J L Heerspink, Avraham Karasik, Marcus Thuresson, Cheli Melzer-Cohen, Gabriel Chodick, Kamlesh Khunti, John P H Wilding, Luis Alberto Garcia Rodriguez, Lucia Cea-Soriano, Shun Kohsaka,[...]. Lancet Diabetes Endocrinol 2020
126
50


Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes.
JingWei Li, Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Brendon L Neuen, Clare Arnott, Roger Simpson, Richard Oh, Kenneth W Mahaffey, Hiddo J L Heerspink. Kidney Int 2020
29
25

Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents.
Vincent L M Esnault, Amr Ekhlas, Catherine Delcroix, Marie-Geneviève Moutel, Jean-Michel Nguyen. J Am Soc Nephrol 2005
81
25

Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial.
Pierpaolo Pellicori, David Fitchett, Mikhail N Kosiborod, Anne P Ofstad, Leo Seman, Bernard Zinman, Isabella Zwiener, Christoph Wanner, Jyothis George, Silvio E Inzucchi,[...]. Eur J Heart Fail 2021
10
25

Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease.
Glenn M Chertow, Priya Vart, Niels Jongs, Robert D Toto, Jose Luis Gorriz, Fan Fan Hou, John J V McMurray, Ricardo Correa-Rotter, Peter Rossing, C David Sjöström,[...]. J Am Soc Nephrol 2021
18
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.